A medical worker examines a patient with traditional Chinese medicine (TCM) therapies at a temporary hospital in Jiangxia District in Wuhan, central China's Hubei Province, Feb. 25, 2020. (Xinhua/Shen Bohan)
A traditional Chinese medicine decoction has been used in treating COVID-19 patients at different stages with varied syndromes in 28 Chinese provincial-regions and has received positive feedback.
BEIJING, March 24 (Xinhua) -- Research on a traditional Chinese medicine (TCM) decoction which has proved effective in treating COVID-19 patients has seen progress, a medical expert said Tuesday.
The TCM decoction named "Qing Fei Pai Du Tang" has come into the spotlight after being repeatedly recommended by the National Health Commission and the National Administration of TCM, said Wang Rongbing, director physician with Beijing Ditan Hospital, at a press conference in Beijing.
A number of articles detailing relevant TCM documents and analyses of the prescription are now available. The basic research on this prescription, such as the active substances and the therapeutic mechanism, is underway, and it takes time, said Wang.
The decoction has been used in treating COVID-19 patients at different stages with varied syndromes in 28 provincial-regions across the country and has received positive feedback. Its application has been extended to suspected cases, according to Wang.
As of Monday, none of the 1,265 confirmed COVID-19 patients under monitoring at 66 designated hospitals in 10 provinces other than Hubei Province had developed from mild cases to severe cases or from common cases to critical cases after using the decoction, Wang noted.
Altogether 1,241 patients, accounting for over 98 percent of the total, had been discharged from hospital after recovery.
Of another 57 severe cases, none of them had developed into critical cases, and 42 of them had been discharged from hospital after recovery with no liver or kidney damage, according to Wang.
Research on the quality standard and production of the mixture and compound products of this prescription has been completed in a bid to promote its clinical application against COVID-19, said Wang. ■
